These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 12449082)

  • 41. Antireward, compulsivity, and addiction: seminal contributions of Dr. Athina Markou to motivational dysregulation in addiction.
    Koob GF
    Psychopharmacology (Berl); 2017 May; 234(9-10):1315-1332. PubMed ID: 28050629
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The reward for placebos: mechanisms underpinning placebo-induced effects on motor performance.
    Brietzke C; Cesario JCS; Hettinga FJ; Pires FO
    Eur J Appl Physiol; 2022 Nov; 122(11):2321-2329. PubMed ID: 36006479
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Selective Role for Dopamine in Learning to Maximize Reward But Not to Minimize Effort: Evidence from Patients with Parkinson's Disease.
    Skvortsova V; Degos B; Welter ML; Vidailhet M; Pessiglione M
    J Neurosci; 2017 Jun; 37(25):6087-6097. PubMed ID: 28539420
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Regionally distinct phasic dopamine release patterns in the striatum during reversal learning.
    Klanker M; Fellinger L; Feenstra M; Willuhn I; Denys D
    Neuroscience; 2017 Mar; 345():110-123. PubMed ID: 27185487
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Role of endogenous cannabinoids in cerebral reward mechanisms].
    Wenger T; Fürst S
    Neuropsychopharmacol Hung; 2004 Mar; 6(1):26-9. PubMed ID: 15125311
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Therapeutic application of transcranial magnetic stimulation in Parkinson's disease: the contribution of expectation.
    Strafella AP; Ko JH; Monchi O
    Neuroimage; 2006 Jul; 31(4):1666-72. PubMed ID: 16545582
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Alterations in brain opiate receptors in Parkinson's disease.
    Reisine TD; Rossor M; Spokes E; Iversen LL; Yamamura HI
    Brain Res; 1979 Sep; 173(2):378-82. PubMed ID: 226215
    [No Abstract]   [Full Text] [Related]  

  • 48. Dopamine synthesis, uptake, metabolism, and receptors: relevance to gene therapy of Parkinson's disease.
    Elsworth JD; Roth RH
    Exp Neurol; 1997 Mar; 144(1):4-9. PubMed ID: 9126143
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dopamine receptors in Parkinson's disease.
    Hassan MN; Thakar JH
    Prog Neuropsychopharmacol Biol Psychiatry; 1988; 12(2-3):173-82. PubMed ID: 3290993
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Characterization of the effects of serotonin on the release of [3H]dopamine from rat nucleus accumbens and striatal slices.
    Nurse B; Russell VA; Taljaard JJ
    Neurochem Res; 1988 May; 13(5):403-7. PubMed ID: 3165497
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The placebo response: neurobiological and clinical issues of neurological relevance.
    Pollo A; Benedetti F
    Prog Brain Res; 2009; 175():283-94. PubMed ID: 19660663
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Understanding how opioids contribute to reward and analgesia.
    Fields HL
    Reg Anesth Pain Med; 2007; 32(3):242-6. PubMed ID: 17543821
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson's disease.
    Boileau I; Guttman M; Rusjan P; Adams JR; Houle S; Tong J; Hornykiewicz O; Furukawa Y; Wilson AA; Kapur S; Kish SJ
    Brain; 2009 May; 132(Pt 5):1366-75. PubMed ID: 19153147
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution.
    Piggott MA; Marshall EF; Thomas N; Lloyd S; Court JA; Jaros E; Burn D; Johnson M; Perry RH; McKeith IG; Ballard C; Perry EK
    Brain; 1999 Aug; 122 ( Pt 8)():1449-68. PubMed ID: 10430831
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The placebo effect on mood and behavior: possible role of opioid and dopamine modulation of the hypothalamic-pituitary-adrenal system.
    Sher L
    Forsch Komplementarmed Klass Naturheilkd; 2003 Apr; 10(2):61-8. PubMed ID: 12808364
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Subthalamic deep brain stimulation does not induce striatal dopamine release in Parkinson's disease.
    Strafella AP; Sadikot AF; Dagher A
    Neuroreport; 2003 Jul; 14(9):1287-9. PubMed ID: 12824777
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Endogenous cannabinoid and opioid systems and their role in nicotine addiction.
    Maldonado R; Berrendero F
    Curr Drug Targets; 2010 Apr; 11(4):440-9. PubMed ID: 20017727
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The ins and outs of the striatum: role in drug addiction.
    Yager LM; Garcia AF; Wunsch AM; Ferguson SM
    Neuroscience; 2015 Aug; 301():529-41. PubMed ID: 26116518
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects.
    Volkow ND; Wang GJ; Fowler JS; Logan J; Gatley SJ; Hitzemann R; Chen AD; Dewey SL; Pappas N
    Nature; 1997 Apr; 386(6627):830-3. PubMed ID: 9126741
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Parkinson's disease and RLS: the dopaminergic bridge.
    Rye DB
    Sleep Med; 2004 May; 5(3):317-28. PubMed ID: 15165542
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.